Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 4 | 2025 | 33 | 2.470 |
Why?
|
| Ovarian Neoplasms | 10 | 2024 | 462 | 1.440 |
Why?
|
| Adenocarcinoma | 3 | 2025 | 1014 | 1.370 |
Why?
|
| Glomus Tumor | 2 | 2024 | 13 | 1.110 |
Why?
|
| Lung Neoplasms | 3 | 2025 | 1538 | 1.010 |
Why?
|
| Juxtaglomerular Apparatus | 1 | 2024 | 7 | 0.910 |
Why?
|
| Synaptophysin | 1 | 2024 | 19 | 0.900 |
Why?
|
| Carcinoma | 3 | 2024 | 299 | 0.900 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 24 | 0.890 |
Why?
|
| Fallopian Tube Neoplasms | 4 | 2024 | 14 | 0.770 |
Why?
|
| Cystadenocarcinoma, Serous | 7 | 2024 | 57 | 0.770 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 59 | 0.770 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 124 | 0.730 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 123 | 0.730 |
Why?
|
| Angiofibroma | 1 | 2021 | 5 | 0.720 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2021 | 10 | 0.710 |
Why?
|
| Carcinoma, Papillary | 1 | 2022 | 93 | 0.710 |
Why?
|
| Gout | 1 | 2024 | 167 | 0.690 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 184 | 0.670 |
Why?
|
| Adnexal Diseases | 1 | 2020 | 23 | 0.670 |
Why?
|
| Kidney Neoplasms | 1 | 2024 | 447 | 0.660 |
Why?
|
| Pleural Effusion | 1 | 2020 | 110 | 0.640 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 531 | 0.630 |
Why?
|
| Carcinoma in Situ | 4 | 2024 | 74 | 0.630 |
Why?
|
| Pneumonia, Aspiration | 1 | 2019 | 18 | 0.630 |
Why?
|
| Foreign-Body Reaction | 1 | 2019 | 17 | 0.630 |
Why?
|
| Aspergillosis | 1 | 2019 | 46 | 0.620 |
Why?
|
| Airway Obstruction | 1 | 2021 | 167 | 0.620 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2019 | 149 | 0.620 |
Why?
|
| Paramyxoviridae Infections | 1 | 2019 | 49 | 0.610 |
Why?
|
| Adenoma | 1 | 2020 | 147 | 0.600 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 81 | 0.580 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2018 | 2 | 0.570 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 219 | 0.550 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 566 | 0.530 |
Why?
|
| Melanoma | 1 | 2023 | 951 | 0.480 |
Why?
|
| Diagnosis, Differential | 4 | 2025 | 1952 | 0.480 |
Why?
|
| Prostatic Neoplasms | 2 | 2025 | 1539 | 0.450 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 280 | 0.330 |
Why?
|
| Humans | 24 | 2025 | 132062 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2024 | 763 | 0.280 |
Why?
|
| Middle Aged | 10 | 2025 | 28964 | 0.270 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1381 | 0.270 |
Why?
|
| Peritoneal Neoplasms | 1 | 2007 | 57 | 0.250 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2025 | 3 | 0.230 |
Why?
|
| DNA, Neoplasm | 2 | 2019 | 295 | 0.220 |
Why?
|
| Aged | 6 | 2025 | 21406 | 0.220 |
Why?
|
| Ovary | 1 | 2007 | 369 | 0.220 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2024 | 119 | 0.220 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2024 | 2 | 0.220 |
Why?
|
| Pancreatic Diseases | 1 | 2024 | 39 | 0.210 |
Why?
|
| Female | 16 | 2025 | 70712 | 0.210 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1658 | 0.200 |
Why?
|
| Pancreas | 1 | 2024 | 222 | 0.200 |
Why?
|
| Genital Neoplasms, Female | 1 | 2003 | 46 | 0.200 |
Why?
|
| Uroplakin II | 1 | 2022 | 1 | 0.190 |
Why?
|
| Male | 7 | 2025 | 64922 | 0.190 |
Why?
|
| Keratins | 1 | 2022 | 52 | 0.190 |
Why?
|
| Urothelium | 1 | 2022 | 59 | 0.180 |
Why?
|
| Cadherins | 1 | 2022 | 179 | 0.170 |
Why?
|
| Respiratory System | 1 | 2021 | 98 | 0.170 |
Why?
|
| Dextrans | 1 | 2019 | 48 | 0.160 |
Why?
|
| Rectum | 1 | 2019 | 114 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 2019 | 132 | 0.150 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 108 | 0.150 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 45 | 0.140 |
Why?
|
| Hematuria | 1 | 2018 | 54 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 729 | 0.140 |
Why?
|
| Taxoids | 1 | 2018 | 71 | 0.140 |
Why?
|
| Deoxycytidine | 1 | 2018 | 83 | 0.140 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 81 | 0.130 |
Why?
|
| Bilirubin | 1 | 2018 | 128 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 719 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 347 | 0.120 |
Why?
|
| Abdominal Pain | 1 | 2018 | 314 | 0.120 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 700 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 794 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2004 | 19 | 0.100 |
Why?
|
| Fallopian Tubes | 2 | 2024 | 76 | 0.100 |
Why?
|
| Adult | 3 | 2024 | 31568 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2648 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1297 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1342 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 319 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2007 | 3418 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2007 | 169 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3834 | 0.060 |
Why?
|
| Cystadenoma, Serous | 1 | 2004 | 7 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 51 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 112 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 81 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 200 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2003 | 4 | 0.050 |
Why?
|
| Genes, ras | 1 | 2003 | 100 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2025 | 670 | 0.050 |
Why?
|
| ROC Curve | 1 | 2003 | 601 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 824 | 0.040 |
Why?
|
| Mutation | 4 | 2019 | 6229 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 1284 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 613 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2019 | 130 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1473 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 688 | 0.030 |
Why?
|
| Cystectomy | 1 | 2018 | 163 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 370 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2018 | 254 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 764 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2019 | 2508 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 1125 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 358 | 0.030 |
Why?
|
| Risk Factors | 1 | 2007 | 10941 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2004 | 221 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 2224 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1647 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2172 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 5009 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1356 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 2192 | 0.010 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2004 | 13 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 85 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2004 | 73 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 140 | 0.010 |
Why?
|
| Clone Cells | 1 | 2004 | 179 | 0.010 |
Why?
|
| ras Proteins | 1 | 2004 | 146 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 98 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 174 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 281 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1045 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 743 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 1077 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1694 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1573 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 808 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1892 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5409 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 1824 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 7102 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 17419 | 0.010 |
Why?
|